Stockreport

Zevra Therapeutics Inc (ZVRA) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ... [Yahoo! Finance]

Zevra Therapeutics, Inc.  (ZVRA) 
PDF Zevra Therapeutics Inc ( NASDAQ:ZVRA ) successfully launched Myle, the first FDA-approved therapy for Niemann-Pick disease type C, with 90 prescription enrollment forms [Read more]